HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration.

Abstract
The results of a patient with exudative age-related macular degeneration who received an intravitreal injection of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Paris, France) in the right eye are described. A complete ocular examination as well as color fundus photography, optical coherence tomography, fluorescein angiography, microperimetry, full-field electroretinography, and multifocal electroretinography were performed and repeated 1 month later. The patient experienced subjective and objective improvement of visual acuity with a decrease in intraretinal and subretinal fluid. Microperimetric improvement also occurred. Electroretinographic changes were noted from baseline to the 30-day follow-up. No adverse events were observed at any time point. Ziv-aflibercept demonstrated short-term safety and efficacy after intravitreal administration for neovascular macular degeneration.
AuthorsJoão Rafael de Oliveira Dias, Camilla Oliveira Xavier, André Maia, Nilva Simeren Bueno de Moraes, Carsten Meyer, Michel Eid Farah, Eduardo Büchele Rodrigues
JournalOphthalmic surgery, lasers & imaging retina (Ophthalmic Surg Lasers Imaging Retina) Vol. 46 Issue 1 Pg. 91-4 (Jan 2015) ISSN: 2325-8179 [Electronic] United States
PMID25559518 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright 2015, SLACK Incorporated.
Chemical References
  • Angiogenesis Inhibitors
  • Recombinant Fusion Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • Receptors, Vascular Endothelial Growth Factor
Topics
  • Aged, 80 and over
  • Angiogenesis Inhibitors (therapeutic use)
  • Electroretinography
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Male
  • Photography
  • Receptors, Vascular Endothelial Growth Factor (therapeutic use)
  • Recombinant Fusion Proteins (therapeutic use)
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)
  • Visual Acuity (physiology)
  • Wet Macular Degeneration (diagnosis, drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: